{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-018477","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.997740+00:00","generated_at":"2026-06-15T13:36:01.503030+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Prelude Therapeutics Q1 2023 net loss $27.7M; cash runway unchanged into Q4 2024","bullets":["Net loss $27.7M ($0.58 loss per share) vs $29.5M ($0.63) in Q1 2022.","Cash, cash equivalents & marketable securities $172.3M; funding operations into Q4 2024.","R&D expenses decreased to $21.8M from $22.8M YoY.","PRT2527 CDK9 inhibitor solid tumor dose escalation complete; RP2D in hematological malignancies expected 2H 2023.","Phase 1 dose escalation of PRT3789 (SMARCA2 degrader) ongoing; oral candidate nomination expected early 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-018477","json":"https://secwatch.observer/filing/0000950170-23-018477.json","markdown":"https://secwatch.observer/filing/0000950170-23-018477.md","text":"https://secwatch.observer/filing/0000950170-23-018477.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000095017023018477/0000950170-23-018477-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000095017023018477/prld-20230508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T13:36:01.503030+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a791eee9cc25177ffb3045a23c5839df2754c37c","claim":"Prelude Therapeutics Inc reported first quarter ended March 31, 2023 results: net income $27.7 million, EPS $0.58 per share.","evidence_excerpt":"Net Loss: For the three months ended March 31, 2023, net loss was $27.7 million, or $0.58 per share compared to $29.5 million, or $0.63 per share, for the prior year period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1678660/000095017023018477/0000950170-23-018477-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Net income","value":"$27.7 million"},{"label":"EPS","value":"$0.58 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}